National survey of patient perspectives on cost discussions.

Authors

Anh Lam

Anh Lam

University of Oklahoma Health Sciences Center, Oklahoma City, OK

Anh Lam, Ryan David Nipp, Jill S. Hasler, Bonnie Y Hu, Gregory J Zahner, Sarina Robbins, Stephanie B. Wheeler, Erin K Tagai, Suzanne M. Miller, Jeffrey M. Peppercorn

Organizations

University of Oklahoma Health Sciences Center, Oklahoma City, OK, The University of Oklahoma Stephenson Cancer Center, Oklahoma City, OK, Fox Chase Cancer Center, Philadelphia, PA, Massachusetts General Hospital, Boston, MA, HealthWell Foundation, Washington, DC, The University of North Carolina at Chapel Hill, Chapel Hill, NC

Research Funding

Other Foundation
HealthWell Foundation

Background: Patients with cancer often experience financial concerns and may seek help from copay assistance programs (CAPs). We sought to describe CAP recipients’ experiences and preferences for cost discussions. Methods: From 10-11/2022, we conducted a national, cross-sectional survey of CAP recipients with a cancer diagnosis or autoimmune condition, which asked about patient perspectives on cost discussions (desire to discuss costs, want doctors to consider out of pocket [OOP] costs, believe doctors should ensure patients can afford treatment prescribed, and report their doctor had discussed costs). We used multivariable logistic regression models to describe factors associated with patient perspectives on cost discussions and explored associations among cost discussion perspectives with financial toxicity (COST tool), depression/anxiety symptoms (PHQ-4), and health literacy. Results: Among 1,566 participants, 71% had cancer and 29% had an autoimmune condition. Of those with cancer, 71% had a hematologic malignancy, 19% had metastatic solid tumor, 4% had non-metastatic solid tumor, and 6% did not disclose cancer type. Although 62% of respondents desired cost discussions, only 32% reported that they took place. Over half (52%) of recipients wanted doctors to consider OOP costs, and 61% believed doctors should ensure patients can afford treatment prescribed. Those with a hematologic malignancy (OR 0.63, p=.007) and those of Hispanic ethnicity (OR 0.42, p=.020) were less likely to desire cost discussions. Those with a hematologic malignancy or metastatic solid tumor were less likely than those with an autoimmune condition to want doctors to consider OOP costs (OR 0.50, p<.001; OR 0.64, p=.040, respectively) and less likely to believe doctors should ensure patients can afford treatment (OR 0.56, p=.001; OR 0.52, p=.004, respectively). Those with a hematologic malignancy (OR 0.59, p=.004), Hispanic ethnicity (OR 0.24, p=.009), or more comorbidities (OR 0.55, p=.011) were less likely to report having cost discussions. Patients with severe financial toxicity were more likely to desire a cost discussion (OR 1.79, p<.001) and to want doctors to consider OOP costs (OR 1.43, p=.017). Depression symptoms were associated with belief that doctors should ensure patients can afford treatment (OR 1.47, p=.038). Those with lower health literacy were more likely to desire discussing costs (OR 1.38, p=.021) and believe doctors should ensure patients can afford treatment (OR 1.32, p=.047). Conclusions: In this large sample of CAP recipients with cancer and autoimmune conditions, most reported a desire for cost discussions and felt that doctors should consider OOP costs while ensuring patients can afford treatment prescribed. However, under one third reported cost discussions took place. We found factors associated with these outcomes, which may help to inform future work regarding patient-clinician discussions about financial concerns.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Quality Care Symposium

Session Type

Poster Session

Session Title

Poster Session A

Track

Quality, Safety, and Implementation Science,Cost, Value, and Policy,Patient Experience,Survivorship

Sub Track

Communication and Shared Decision-Making Research

Citation

JCO Oncol Pract 19, 2023 (suppl 11; abstr 310)

DOI

10.1200/OP.2023.19.11_suppl.310

Abstract #

310

Poster Bd #

D3

Abstract Disclosures

Similar Abstracts

First Author: Ying Liu

First Author: Courtney Daum

First Author: Ayobami Gbenga Olafimihan